These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 23150720)
1. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. Shi M; Lu LG; Fang WQ; Guo RP; Chen MS; Li Y; Luo J; Xu L; Zou RH; Lin XJ; Zhang YQ J Natl Cancer Inst; 2013 Jan; 105(1):59-68. PubMed ID: 23150720 [TBL] [Abstract][Full Text] [Related]
2. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. He M; Li Q; Shen J; Tan G; Li Q; Lai J; Wei W; Zhang Y; Zou R; Chen M; Guo R; Shi M Cancer Med; 2019 Aug; 8(9):4200-4213. PubMed ID: 31207163 [TBL] [Abstract][Full Text] [Related]
3. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Lu W; Li Y; He X; Chen Y Hepatogastroenterology; 2003; 50(54):2079-83. PubMed ID: 14696468 [TBL] [Abstract][Full Text] [Related]
4. Re: roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. Chan SL; Hui EP; Yu S; Yeo W J Natl Cancer Inst; 2013 Apr; 105(8):580. PubMed ID: 23503599 [No Abstract] [Full Text] [Related]
5. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. Takayasu K; Arii S; Ikai I; Kudo M; Matsuyama Y; Kojiro M; Makuuchi M; AJR Am J Roentgenol; 2010 Mar; 194(3):830-7. PubMed ID: 20173167 [TBL] [Abstract][Full Text] [Related]
6. Preoperative chemolipiodolization of the whole liver for hepatocellular carcinoma. Kaibori M; Tanigawa N; Matsui Y; Kwon AH; Sawada S; Kamiyama Y Anticancer Res; 2004; 24(3b):1929-33. PubMed ID: 15274379 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy. Ueno M; Uchiyama K; Ozawa S; Hayami S; Shigekawa Y; Tani M; Yamaue H Ann Surg Oncol; 2011 Dec; 18(13):3624-31. PubMed ID: 21614626 [TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. Yu SJ; Lee JH; Jang ES; Cho EJ; Kwak MS; Yoon JH; Lee HS; Kim CY; Kim YJ Radiology; 2013 May; 267(2):638-47. PubMed ID: 23440326 [TBL] [Abstract][Full Text] [Related]
9. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Imai N; Ikeda K; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921 [TBL] [Abstract][Full Text] [Related]
10. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. Mouli SK; Hickey R; Thornburg B; Sato KT; Desai K; Gabr A; Kallini JR; Niemeri H; Kircher S; Mulcahy MF; Benson Iii AB; Gupta R; Salem R; Lewandowski RJ J Vasc Interv Radiol; 2016 Sep; 27(9):1279-1287. PubMed ID: 27062355 [TBL] [Abstract][Full Text] [Related]
11. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y; Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600 [TBL] [Abstract][Full Text] [Related]
12. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. Ikeda M; Arai Y; Park SJ; Takeuchi Y; Anai H; Kim JK; Inaba Y; Aramaki T; Kwon SH; Yamamoto S; Okusaka T; ; J Vasc Interv Radiol; 2013 Apr; 24(4):490-500. PubMed ID: 23466316 [TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. Brown DB; Pilgram TK; Darcy MD; Fundakowski CE; Lisker-Melman M; Chapman WC; Crippin JS J Vasc Interv Radiol; 2005 Dec; 16(12):1661-6. PubMed ID: 16371533 [TBL] [Abstract][Full Text] [Related]
14. Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial. Liu B; Huang JW; Li Y; Hu BS; He X; Zhao W; Zheng YB; Lu LG Oncology; 2015; 89(1):23-30. PubMed ID: 25613214 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. He MK; Zou RH; Wei W; Shen JX; Zhao M; Zhang YF; Lin XJ; Zhang YJ; Guo RP; Shi M J Vasc Interv Radiol; 2018 Aug; 29(8):1068-1077.e2. PubMed ID: 30042075 [TBL] [Abstract][Full Text] [Related]